What does the evidence say about Berberine Supplementation Lipid Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Berberine Supplementation Lipid Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Although preclinical evidence is promising, no systematic review has previously synthesised evidence from randomised controlled trials (RCTs) in humans. [Candrea AR (2026); evidence level 1] - This review aimed to evaluate the effects of berberine supplementation on gut microbiota and to explore associated cardiometabolic, inflammatory, and immunological changes. [Candrea AR (2026); evidence level 1] - Background/Aim : Berberine, an isoquinoline alkaloid widely used in traditional medicine, has attracted considerable interest for its capacity to modulate the gut microbiota and improve cardiometabolic outcomes. [Candrea AR (2026); evidence level 1] - In vivo experiments showed that BBR improved bone mineral density and trabecular microarchitecture, and upregulated osteogenic markers (COL1 and BMP2). [Chao S (2026); evidence level 4] - Overall, these findings suggest that the attenuation of bone loss by BBR may be associated with alterations in the gut microbiota-glycerophospholipid metabolic axis, supporting its potential as a functional food ingredient for bone health. [Chao S (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.